Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium.

This study was designed to develop methods for monitoring of the selective factor Xa inhibitor fondaparinux sodium (ARIXTRA) based on standard laboratory methods for the chromogenic determination of the anti-factor Xa activity of low molecular weight heparin. To examine the biologic activity of fondaparinux in comparison to its plasma concentration, 2 methods were investigated: 1 working with the addition of antithrombin (AT), the other without exogenous AT. Both methods showed a linear relationship of fondaparinux concentration and OD/min on a log-lin scale in the range from 0.

Univariate tolerance regions for fibrinogen, antithrombin III, protein C, protein S, plasminogen and alpha 2-antiplasmin in children using the new Automated Coagulation Laboratory (ACL) method.

To avoid misclassification of lowered or enhanced coagulation proteins in childhood the purpose of this study was to establish functional normal ranges for healthy children aged 6 months to 16 years. PT, aPTT, fibrinogen, antithrombin III, protein C, protein S, plasminogen and alpha 2-antiplasmin were tested using the new Automated Coagulation Laboratory (ACL) method. Values for PT, aPTT, fibrinogen, antithrombin III, plasminogen and alpha 2-antiplasmin were closely comparable in all children although we found a minimum range of 61% in children aged 8 to 16 years in plasma concentrations of alpha 2-antiplasmin.

Regression of deep vein thrombosis by i.v.-administration of a low molecular weight heparin--results of a pilot study.

Twenty-five patients with phlebographically confirmed deep vein thrombosis of the lower limb were treated with intravenous infusions of low molecular weight heparin for 7 to 29 days. The mean dosage was 15.2 +/- 3.